miércoles, 29 de marzo de 2023

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis | NEJM

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis | NEJM

No hay comentarios:

Publicar un comentario